The DIVA immunoassay for veterinary herpesviruses like PRV and BHV-1 works through a competitive ELISA that detects antibodies against a viral protein deliberately deleted from the vaccine.
In this format, a purified recombinant version of the deleted protein (e.g., gE or gI) is coated on the solid phase. A sample is added together with an enzyme‑labeled monoclonal antibody specific to that same protein. If the animal was infected with wild‑type virus, its circulating antibodies will block the conjugate, producing a low signal; vaccinated animals lack those antibodies, so the conjugate binds fully and generates a high signal. The assay’s success depends on two raw material pillars: a high‑purity recombinant antigen of the deleted target and a high‑affinity enzyme‑conjugated monoclonal antibody that recognizes a single, stable epitope.
DIVA diagnostics combine a gene‑deleted marker vaccine with a blocking ELISA that zeroes in on the missing protein. The entire differentiation power rests on the specific interaction between a carefully engineered recombinant antigen and a precisely matched enzyme‑labeled monoclonal antibody—without these, the test cannot reliably separate vaccinated from field‑infected animals.
The DIVA Strategy: Marker Vaccines and Deleted Proteins
Why Gene‑Deleted Vaccines Are Essential
Conventional vaccines generate the same antibody profile as a natural infection, making it impossible to tell protected animals from carriers. The DIVA principle solves this by creating marker vaccines that lack one or more non‑essential genes. The vaccinated animal never encounters the corresponding protein, so it remains seronegative for that specific marker while still being protected against clinical disease.
The Specific Target Proteins for Herpesviruses
For Pseudorabies Virus (PRV), the deleted gene is often the glycoprotein I (gI) gene. For Bovine Herpesvirus 1 (BHV‑1), the most common deletion is the glycoprotein E (gE) gene. These proteins are highly immunogenic during a natural infection, meaning field‑exposed animals reliably produce strong antibody responses against them, giving the diagnostic test a clear target to chase.
How the Competitive ELISA Works
Capturing the Marker Protein
Microwells are coated with the recombinant deleted protein—for instance, purified BHV‑1 gE antigen. This solid‑phase antigen must present the epitope in its native conformation to ensure that antibodies from field‑infected sera recognize and bind it exactly as they would on the intact virus.
The Competition Step
The test sample is incubated together with an enzyme‑conjugated monoclonal antibody (commonly horseradish peroxidase, HRPO) that targets the same marker epitope. If the animal was infected with a wild‑type field strain, anti‑gE antibodies in the sample will compete with and block the conjugate, preventing it from binding to the coated antigen. If the animal was vaccinated with the gE‑deleted vaccine, no anti‑gE antibodies are present, and the conjugate binds unhindered.
Reading the Signal
After washing and adding a substrate, a strong color signal indicates the conjugate bound successfully—meaning the animal is negative for the marker and was either vaccinated or uninfected. A weak or absent signal tells the opposite story: the sample contained blocking antibodies, proving the animal was exposed to the field virus.
The Non‑Negotiable Raw Materials
High‑Purity Recombinant Antigen
The capture antigen must be the exact deleted protein expressed in a system that retains its immunological epitopes. Any contamination with host‑cell proteins or misfolded variants can cause non‑specific binding and false‑positive results. The antigen also has to be supplied in a format that adsorbs uniformly to ELISA plates, ensuring well‑to‑well consistency.
Enzyme‑Conjugated Monoclonal Antibody
The second essential ingredient is a monoclonal antibody that binds a single, conserved epitope on the marker protein and is covalently linked to a detection enzyme like HRPO. This conjugate must exhibit high affinity and specificity—if it cross‑reacts with other viral proteins or if its affinity is too low, the competitive signal window collapses, and infected animals might be misclassified as vaccinated. Stability of the enzyme label under storage and assay conditions is equally critical.
Understanding the Trade‑offs
The Risk of Incomplete Genetic Deletion
If the marker vaccine manufacturer does not completely delete the target gene—or if a field strain undergoes recombination—vaccinated animals might develop trace antibodies against the marker protein. This can erode the assay’s specificity, leading to false positives that undermine control programs.
Purity Challenges with Recombinant Proteins
Producing recombinant gE or gI in heterologous systems (e.g., E. coli, insect cells) can introduce incorrect folding or missing post‑translational modifications. An antigen that does not perfectly mimic the native viral protein will fail to capture all the relevant serum antibodies, reducing test sensitivity.
Conjugate Batch‑to‑Batch Consistency
Slight variations in conjugation chemistry or monoclonal antibody affinity can shift the competitive balance. Developers must rigorously validate each lot of conjugate with a panel of known positive and negative samples to maintain the same differentiation accuracy over time.
Making the Right Choice for Your Assay Development
Depending on where your focus lies, prioritize these factors when sourcing raw materials:
- If your primary focus is building a robust PRV DIVA test: Demand a recombinant gI antigen with documented purity above 95% and an anti‑gI monoclonal conjugate that shows complete blocking in the presence of high‑titer field serum.
- If your primary focus is BHV‑1 surveillance in cattle: Select an HRPO‑conjugated anti‑gE monoclonal antibody that targets an epitope conserved across all circulating field strains, paired with a gE antigen that delivers a signal‑to‑noise ratio greater than 10.
- If your primary focus is scaling a DIVA platform to new herpesviruses: Start by identifying the exact gene deletion in the companion vaccine, then source the corresponding recombinant protein and a matched, epitope‑specific conjugate with verified lot‑traceable performance.
With rigorous attention to the quality and compatibility of these two raw materials, you can deliver a diagnostic that gives veterinarians unambiguous answers—protecting herds through vaccination while enabling the precise surveillance needed to eliminate wild‑type virus.
Summary Table:
| Target Virus | Deleted Vaccine Marker | Essential Raw Materials | Assay Principle |
|---|---|---|---|
| Pseudorabies Virus (PRV) | Glycoprotein I (gI) | High-purity Recombinant gI Antigen & Anti-gI HRPO Conjugate | Competitive Blocking ELISA |
| Bovine Herpesvirus 1 (BHV-1) | Glycoprotein E (gE) | High-purity Recombinant gE Antigen & Anti-gE HRPO Conjugate | Competitive Blocking ELISA |
Accelerate Your Veterinary DIVA Assay Development with CamelBio
Developing high-performance DIVA immunoassay kits for PRV or BHV-1 requires superior recombinant antigens and precisely matched, high-affinity monoclonal antibody conjugates. CamelBio provides diagnostic manufacturers, labs, and research institutes with one-stop access to premium IVD raw materials, technical services, and expert consulting—covering every stage from concept to clinic.
Ready to elevate your diagnostic accuracy and ensure lot-to-lot consistency? Contact us today to request sample materials or consult with our technical team!